Lenvatinib Mesylate Intermediate CAS 205448-65-3 Tsarkake> 98.0% (HPLC) Factory
Ruifu Chemical Supply Lenvatinib Mesylate Matsakaici Tare da Babban Tsafta
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1- (2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dion CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Sunan Sinadari | Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate |
Makamantu | 1,4-Dihydro-7-Methoxy-4-Oxo-6-Quinolinecarboxylic Acid Methyl Ester;7-Methoxy-4-Oxo-1,4-Dihydro-Quinoline-6-Carboxylic Acid Methyl Ester;Matsakaicin Lenvatinib 3 |
Lambar CAS | 205448-65-3 |
Lambar CAT | RF-PI1973 |
Matsayin Hannun jari | A cikin Hannun jari, Ƙarfin Samar da 50 MT/Shekara |
Tsarin kwayoyin halitta | Saukewa: C12H11NO4 |
Nauyin Kwayoyin Halitta | 233.22 |
Wurin Tafasa | 421.0 ± 45.0 ℃ |
Yawan yawa | 1.267± 0.060 g/cm3 |
Alamar | Ruifu Chemical |
Abu | Ƙayyadaddun bayanai |
Bayyanar | Kashe-Fara zuwa Foda mai launin rawaya |
Tsarkake / Hanyar Bincike | 98.0% (HPLC) |
Asara akan bushewa | <1.00% |
Ragowa akan Ignition | <0.50% |
Jimlar ƙazanta | <2.00% |
H-NMR | Yayi daidai da Tsarin |
Matsayin Gwaji | Matsayin Kasuwanci |
Amfani | Matsakaicin Magunguna |
Kunshin: Bottle, Aluminum tsare jakar, 25kg / kwali Drum, ko bisa ga abokin ciniki ta bukata
Yanayin Ajiya:Ajiye a cikin kwantena da aka rufe a wuri mai sanyi da bushe;Kare daga haske da danshi
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate (CAS: 205448-65-3) matsakanci ne na Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib, wanda ake sayar da shi a ƙarƙashin sunan alamar Lenvima da sauransu, magani ne na maganin ciwon daji don maganin wasu nau'in ciwon daji na thyroid da sauran ciwon daji.Eisai Co. ne ya haɓaka shi kuma yana aiki azaman mai hana kinase mai yawa akan VEGFR1, VEGFR2 da VEGFR3 kinases.Lenvatinib an yarda da shi (tun 2015) don maganin bambance-bambancen ciwon daji na thyroid wanda shine ko dai a cikin gida ko kuma metastatic, ci gaba, kuma bai amsa magani tare da iodine radioactive (radioiodine).A cikin watan Mayu 2016, Hukumar Abinci da Magunguna ta Amurka (FDA) ta amince da shi (a hade tare da everolimus) don maganin ci-gaban ciwon daji na renal cell bayan daya kafin maganin angiogenic.An kuma yarda da maganin a cikin Amurka da Tarayyar Turai don ciwon hanta wanda ba za a iya cirewa ta hanyar tiyata a cikin marasa lafiya waɗanda ba su sami maganin ciwon daji ta baki ko allura ba.